Answers are grounded in this paper and cite their sources.
Compares blood-based biomarkers and prognostic factors in inflammatory and non-inflammatory breast cancer.
Inflammatory breast cancer (IBC) is a rare, aggressive disease with poorly understood biology. To provide a comprehensive characterization of blood-based biomarkers in IBC, we retrospectively analyzed 341 metastatic breast cancer patients (83 IBC, 258 non-IBC). Circulating tumor cells (CTCs), CTC clusters, cytokeratin + /CD45+ cells (DPcells), and tumor-derived extracellular vesicles (tdEVs) were evaluated. Matched circulating tumor DNA (ctDNA) data were available for 59 IBC and 110 non-IBC. Analyte distributions and overall survival (OS) association were compared by IBC status. Circulating cellular analytes showed similar distributions, except for lower tdEVs in IBC. CTCs and tdEVs were associated with OS irrespective of IBC status, whereas DPcells only in IBC. TP53 (63%), PIK3CA (29%), and MYC (17%) were the most frequently altered genes in IBC. TP53 sequence variants (SVs; SNVs/indels) and CCNE1 / MYC CNVs were enriched in IBC, but after adjusting for confounders, only PIK3CA SVs remained significantly less frequent. Network analysis identified TP53 SVs as key node in IBC, co-occurring with a CNV module ( MYC / CCNE1 / PIK3CA / FGFR1 ) with higher centrality in IBC than non-IBC. In multivariable analyses, PIK3CA and MYC CNVs were associated with worse OS. A clinical–ctDNA model showed strong prognostic performance, validated in an independent IBC cohort ( n = 39). Overall, integrated liquid biopsy profiling unveiled distinct IBC features and identified prognostic biomarkers.
No takes yet. Share an insight, caveat, or question.
Nicolò et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: